title: CML may not be part of HUS.
authors.forename: J H
authors.initials: JH
authors.lastname: Lipton
authors.forename: M
authors.initials: M
authors.lastname: Minden
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D016026:Bone Marrow Transplantation; D018450:Disease Progression; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced / Q000209:etiology*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007370:Interferon Type I / Q000009:adverse effects; D016898:Interferon-alpha / Q000009:adverse effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D014182:Transplantation, Autologous
chemical_list: D007370:Interferon Type I; D016898:Interferon-alpha; D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006918:Hydroxyurea